Positive News SentimentPositive NewsNASDAQ:INMB INmune Bio (INMB) Stock Forecast, Price & News $6.85 -0.16 (-2.28%) (As of 01:04 PM ET) Add Compare Share Share Today's Range$6.75▼$7.4550-Day Range$6.61▼$8.9552-Week Range$5.75▼$11.26Volume26,389 shsAverage Volume53,970 shsMarket Capitalization$123.44 millionP/E RatioN/ADividend YieldN/APrice Target$16.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media INmune Bio MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside129.9% Upside$16.00 Price TargetShort InterestBearish11.51% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$110,100 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.86 out of 5 starsMedical Sector767th out of 972 stocksBiological Products, Except Diagnostic Industry124th out of 158 stocks 3.5 Analyst's Opinion Consensus RatingINmune Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.00, INmune Bio has a forecasted upside of 129.9% from its current price of $6.96.Amount of Analyst CoverageINmune Bio has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.51% of the float of INmune Bio has been sold short.Short Interest Ratio / Days to CoverINmune Bio has a short interest ratio ("days to cover") of 19.6, which indicates bearish sentiment.Change versus previous monthShort interest in INmune Bio has recently decreased by 1.75%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldINmune Bio does not currently pay a dividend.Dividend GrowthINmune Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INMB. Previous Next 2.7 News and Social Media Coverage News SentimentINmune Bio has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for INmune Bio this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for INMB on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, INmune Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $110,100.00 in company stock.Percentage Held by Insiders36.10% of the stock of INmune Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 12.13% of the stock of INmune Bio is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of INmune Bio is -4.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of INmune Bio is -4.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioINmune Bio has a P/B Ratio of 2.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About INmune Bio (NASDAQ:INMB) StockINmune Bio, Inc., a clinical-stage immunology company, focuses on reprogramming the patient's innate immune system to treat cancer and neurodegenerative diseases. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma solid tumor and patients with high-risk myelodysplastic syndrome; INB03 to treat patients with cancers that express MUC4, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers; and XPro1595 for the treatment of Alzheimer's disease and Treatment Resistant Depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.Read More INMB Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INMB Stock News HeadlinesSeptember 7, 2023 | finance.yahoo.comINmune Bio Inc. to Present at Baird Global Healthcare Conference and H.C Wainwright 25th Annual Global Investment ConferenceSeptember 6, 2023 | markets.businessinsider.comInmune Bio (INMB) Receives a Buy from BTIGSeptember 29, 2023 | PressReach (Ad)This Stock's a Sleeping GiantThe stock everyone has their eye on - discover why it's the talk of the investment world. September 5, 2023 | finance.yahoo.comINmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer’s DiseaseAugust 27, 2023 | finance.yahoo.comRetail investors account for 44% of INmune Bio, Inc.'s (NASDAQ:INMB) ownership, while insiders account for 29%August 8, 2023 | finance.yahoo.comINmune Bio, Inc. (NASDAQ:INMB) Q2 2023 Earnings Call TranscriptAugust 8, 2023 | finance.yahoo.comQ2 2023 INmune Bio Inc Earnings CallAugust 7, 2023 | msn.comINmune Bio GAAP EPS of -$0.36 beats by $0.04September 29, 2023 | PressReach (Ad)This Stock's a Sleeping GiantThe stock everyone has their eye on - discover why it's the talk of the investment world. August 7, 2023 | finance.yahoo.comINmune Bio Inc. Announces Second Quarter 2023 Results and Provides Business UpdateAugust 4, 2023 | benzinga.comEarnings Outlook For INmune BioAugust 1, 2023 | finance.yahoo.comINmune Bio Inc. to Present at the BTIG Virtual Biotechnology ConferenceAugust 1, 2023 | finance.yahoo.comINmune Bio Inc. to Present at the BTIG Virtual Biotechnology ConferenceJuly 31, 2023 | finance.yahoo.comINmune Bio, Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on Monday, August 7July 29, 2023 | markets.businessinsider.comMaxim Group Sticks to Its Buy Rating for Inmune Bio (INMB)July 12, 2023 | finance.yahoo.comINmune Bio Inc. to Deliver Keynote Talk at 5th World Aging and Rejuvenation Conference.July 11, 2023 | finance.yahoo.comINmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in Gray Matter in Patients with Alzheimer’s DiseaseJuly 10, 2023 | finance.yahoo.comINmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro™ Promotes Remyelination by Affecting Astroglial and Microglial BiologyJune 13, 2023 | benzinga.comINmune Bio – Helping Your Own Cells Fight Cancer And Reverse Alzheimer's DiseaseJune 2, 2023 | proactiveinvestors.comINmune Bio's Alzheimer's treatment merits a high-upside price target, analysts sayMay 24, 2023 | technews.tmcnet.comINmune Bio Inc.'s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at International Society of Cell & Gene TherapyMay 24, 2023 | finance.yahoo.comINmune Bio Inc.’s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at International Society of Cell & Gene TherapyMay 13, 2023 | marketwatch.com8-K: Inmune Bio, Inc.May 9, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Baxter International (BAX), Cerus (CERS) and Inmune Bio (INMB)May 8, 2023 | seekingalpha.comINmune Bio gets FDA IND approval for prostate cancer immunotherapyMay 8, 2023 | finance.yahoo.comINmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune™, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate CancerMay 5, 2023 | finance.yahoo.comINmune Bio First Quarter 2023 Earnings: US$0.36 loss per share (vs US$0.39 loss in 1Q 2022)See More Headlines Receive INMB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for INmune Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address INMB Company Calendar Last Earnings8/07/2023Today9/29/2023Next Earnings (Estimated)11/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:INMB CUSIPN/A CIK1711754 Webwww.inmunebio.com Phone(858) 964-3720FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Forecast$16.00 High Stock Price Forecast$16.00 Low Stock Price Forecast$16.00 Forecasted Upside/Downside+128.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,300,000.00 Net Margins-9,532.26% Pretax Margin-9,532.26% Return on Equity-46.30% Return on Assets-34.39% Debt Debt-to-Equity Ratio0.10 Current Ratio4.03 Quick Ratio4.03 Sales & Book Value Annual Sales$370,000.00 Price / Sales341.41 Cash FlowN/A Price / Cash FlowN/A Book Value$3.35 per share Price / Book2.09Miscellaneous Outstanding Shares18,020,000Free Float11,516,000Market Cap$126.32 million OptionableNot Optionable Beta1.95 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Raymond Joseph Tesi M.D. (Age 67)Co-Founder, Pres, CEO, Chief Medical Officer & Chairman Comp: $591.5kMr. David J. Moss M.B.A. (Age 53)CFO, Treasurer & Sec. Comp: $445.16kDr. Mark William Lowdell BSc (Age 60)FRCPath, MICR, MSc, Ph.D., Chief Scientific Officer & Chief Manufacturing Officer Comp: $152.01kMr. Joshua S. Schoonover Esq.Assoc. Gen. CounselDr. Christopher J. BarnumHead of NeuroscienceKey CompetitorsOmega TherapeuticsNASDAQ:OMGATalaris TherapeuticsNASDAQ:TALSTScan TherapeuticsNASDAQ:TCRXCentury TherapeuticsNASDAQ:IPSCSangamo TherapeuticsNASDAQ:SGMOView All CompetitorsInsiders & InstitutionsOsaic Holdings Inc.Bought 3,265 shares on 8/21/2023Ownership: 0.062%Royal Bank of CanadaBought 9,769 shares on 8/15/2023Ownership: 0.390%Citadel Advisors LLCBought 1,600 shares on 8/15/2023Ownership: 0.000%BlackRock Inc.Bought 4,909 shares on 8/11/2023Ownership: 1.330%Geode Capital Management LLCBought 11,023 shares on 8/11/2023Ownership: 0.858%View All Insider TransactionsView All Institutional Transactions INMB Stock - Frequently Asked Questions Should I buy or sell INmune Bio stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for INmune Bio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" INMB shares. View INMB analyst ratings or view top-rated stocks. What is INmune Bio's stock price forecast for 2023? 1 equities research analysts have issued 1-year price objectives for INmune Bio's shares. Their INMB share price forecasts range from $16.00 to $16.00. On average, they predict the company's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 128.2% from the stock's current price. View analysts price targets for INMB or view top-rated stocks among Wall Street analysts. How have INMB shares performed in 2023? INmune Bio's stock was trading at $6.34 at the beginning of 2023. Since then, INMB shares have increased by 10.6% and is now trading at $7.01. View the best growth stocks for 2023 here. When is INmune Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023. View our INMB earnings forecast. How were INmune Bio's earnings last quarter? INmune Bio, Inc. (NASDAQ:INMB) posted its quarterly earnings data on Monday, August, 7th. The company reported ($0.36) earnings per share for the quarter. The business had revenue of $0.05 million for the quarter. INmune Bio had a negative trailing twelve-month return on equity of 46.30% and a negative net margin of 9,532.26%. What other stocks do shareholders of INmune Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other INmune Bio investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Cidara Therapeutics (CDTX), Gilead Sciences (GILD), Cisco Systems (CSCO), Vaxart (VXRT), Micron Technology (MU), Novavax (NVAX) and SCYNEXIS (SCYX). What is INmune Bio's stock symbol? INmune Bio trades on the NASDAQ under the ticker symbol "INMB." How do I buy shares of INmune Bio? Shares of INMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is INmune Bio's stock price today? One share of INMB stock can currently be purchased for approximately $7.01. How much money does INmune Bio make? INmune Bio (NASDAQ:INMB) has a market capitalization of $126.32 million and generates $370,000.00 in revenue each year. The company earns $-27,300,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis. How can I contact INmune Bio? INmune Bio's mailing address is 1200 PROSPECT STREET SUITE 525, LA JOLLA CA, 92037. The official website for the company is www.inmunebio.com. The company can be reached via phone at (858) 964-3720 or via email at james@haydenir.com. This page (NASDAQ:INMB) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INmune Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.